With so many patients relying on novel therapeutics for neurological disorders, the stakes are high when therapies reach the clinic. The best way to improve your chance for success is to design rigorous preclinical studies that include reproducible endpoints and robust biomarkers that predict clinical efficacy.
Charles River hopes you join us as we further explore this topic in a full day of engaging presentations and stimulating discussion with notable neuroscientists from biotech, pharma, and academia. During this scientific symposium, you’ll learn more about the current state of biomarkers for widely studied neurological disorders, including neurodegeneration and psychiatric disease, and learn how to develop robust endpoints that can be used in clinical trials. Our agenda will conclude with a networking reception and tours of our new neuroscience-focused site.
Register now at http://www2.criver.com/translationalbiomarkers2018 to reserve your spot today.